IMO it is difficult to make money in Europe in any event. It is an easier market than the U.S. to enter, but difficult to make money there. The markets are fragmented by country, and at least in countries like Spain again fragmented by region within the country. To make good money, CRY needs lots of sales plus good margins. Related to this is that I suspect that part of the reason for poor historic PerClot sales is the fragmented nature of the European market too. The earnings transcript made it sound a little like the good horse BioFoam has been sent to the glue factory. Also, to introduce a new product into a fragmented market adds to the complexity, so it would seem anyway. Buckeye, thank you for your response on this matter. If you get this sorted out better, please post.